by Rosa Castro | Jun 30, 2022 | #A2Medicines, Monkeypox, The View from EPHA, Universal Access and Affordable Medicines | Latest Developments
“With HERA up and running, the EU has significantly reinforced its capacity to respond and address new health threats decisively”. This is what Health Commissioner Stella Kyriakides said on 28 June 2022 when she announced that the first batch of monkeypox vaccines...
by European Public Health Alliance | Jun 30, 2022 | Universal Access and Affordable Medicines | Analysis & Opinion
By Dr Ward Rommel, Chair, Access to Medicines Task Force, Association of European Cancer Leagues (ECL) The research and innovation pathway for cancer medicines is challenging from basic research to market access. These challenges comprise high unmet needs, disparities...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article Jaume Vidal, Senior Policy Advisor at Health Action International (HAI) In October 2020 in the midst of the COVID-19 pandemic, South Africa and India submitted a proposal to waiver certain dispositions of the Trade- Related aspects of Intellectual...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article by Ancel·la Santos, Senior Health Policy Officer, The European Consumer Organisation (BEUC) To ensure recovery when facing health issues and a better quality of life among European citizens, it is essential that people get timely access to medicines and...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article by Charlotte Roffiaen, European Policy Advisor at France Assos Santé For many years, the increasing prices of innovative medicines have focused the attention of the European public health community. Affordability issues were threatening both patient...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Article by Julia Aube, Policy Trainee for Healthcare Delivery The COVID-19 pandemic has jeopardised the access and availability of medicines in the EU, therefore, making the EU more resilient regarding the supply of pharmaceuticals is a key objective of...
